BMS Psoriasis Drug Shows Positive Phase 3 Results
Bristol Myers Squibb (BMS) has reported positive results from a late-stage trial of its investigational drug, BMS-986165 (deucravacitinib), for treating moderate-to-severe plaque psoriasis.
Deucravacitinib works by inhibiting the tyrosine kinase 2 (TYK2) enzyme, which is linked to an immune response that causes skin inflammation.
The drug reduced the severity of psoriasis by 75 percent in patients vs. placebo. It also demonstrated better efficacy in a comparison with Amgen’s Otezla (apremilast), BMS said.
The company is investigating deucravacitinib for a wide range of autoimmune diseases. It will release results from a phase 2 study of patients with psoriatic arthritis later this week.